Ketamine has been making headlines for years, from the death of actor Matthew Perry to Elon Musk's reported microdosing, to its portrayal in Hulu's "The Secret Lives of Mormon Wives." ...

Atai Life Sciences is making incremental progress towards opening door for a first psychedelic treatment for depression. Read ...

The FDA has approved Janssen’s antidepressant nasal spray Spravato, making it the first new type of depression treatment to hit the market in 30 years – although its use will be restricted to ...

Atai Life Sciences’ psychedelic drug has successfully reduced the symptoms of depression in a phase 2 study, triggering the next stage of the biotech’s planned merger with mental health company ...

Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression (TRD) too high to offer value for money, says a US cost-effectiveness body. The Institute for Clinical ...

This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the ...

Life Sciences & Beckley Psytech announce positive results from phase 2b study of BPL-003 in patients with treatment-resistant depression: New York Wednesday, July 2, 2025, 10 ...

Good morning, it’s the third of July. This newsletter will be off tomorrow for the holiday and — surprise — all of next week.

Positive study results in Phase 2 lead to a green light for the companies’ combination and plans to move their nasal spray ...